DISPOSITION OF AMPIROXICAM, A PRODRUG OF PIROXICAM, IN MAN
DISPOSITION OF AMPIROXICAM, A PRODRUG OF PIROXICAM, IN MAN
复制标题
DOI：
10.3109/00498259009046880
复制
发表时间：
1990-06-01
期刊：
影响因子：
1.8
通讯作者：
BROWDER, IW
中科院分区：
文献类型：
--
作者：
FALKNER, FC;TWOMEY, TM;BROWDER, IW
1. 吡洛昔康是有效抗炎药吡洛昔康的前药，口服后完全转化为吡洛昔康。2. 在临床剂量下，没有检测到人对吡洛昔康的门静脉或全身暴露，表明在吸收过程中完全转化为吡洛昔康。3. 吡洛昔康给药后的药代动力学与吡洛昔康给药后的药代动力学基本相同，只是给药后Cmax略低，tmax稍长。
1. Ampiroxicam, a prodrug of the effective anti-inflammatory agent piroxicam, was completely converted to piroxicam after oral administration to man. 2. At clinical doses there was no detectable portal or systemic exposure of man to ampiroxicam, indicating that conversion to piroxicam was complete during the absorption process. 3. The pharmacokinetics of piroxicam from ampiroxicam were essentially the same as those after piroxicam itself except that Cmax was slighlty lower and tmax was slightly longer after administration of ampiroxicam.